Anti-osteoporosis Therapy & Fracture Healing Market

Anti-osteoporosis Therapy & Fracture Healing Market by Types (Ibandronate, Biophosphonates, Zoledronic Acid, Alendronate, Risedronate, Selective Estrogen Receptor Modulators [Strontium Ranelete and Raloxifene], and Others), Applications (Injectable, Oral, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2339
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 178
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global anti-osteoporosis therapy & fracture healing market size is projected to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising cases of osteoporosis and growing number of road accidents.


Anti-osteoporosis Therapy & Fracture Healing Market summary

Osteoporosis is a common disease caused by a decrease in bone mineral density, which increases the risk of fractures. The spine, hip, shoulder, and forearm of the human body can be normally affected due to the disorder. Furthermore, due to this condition, patients are unable to move and, in the long-term consequences, bed-ridden, which would lead to death eventually. X-ray and radiography tests along with a bone density test are among the major diagnostic procedures for osteoporosis. As per a report by the International Osteoporosis Foundation (IOF), one out of every three women over the age of 50 and one out of every five men over the age of 65 are likely to suffer from osteoporosis disorder. Furthermore, by 2050, the number cases are expected to increase in men and women by 310% and 240% respectively.

The primary cause of the disorder is due to the failure of body mechanism to produce new bones in the replacement of old bones. Furthermore, excessive bone absorption in the body as well as a shortage of calcium and vitamin D are crucial variables that increase the risk of osteoporosis. Moreover, due to a lack of vitamins and minerals, the body is unable to absorb calcium, resulting of which it increases the risk of cracks and fragility of the bone. In addition, reduced estrogen levels among women in post menopause and testosterone levels in males raise the risk of osteoporosis. Due to the COVID-19 pandemics situation worldwide, the anti- osteoporosis & fracture healing market is expected to get affected, as the lockdown is being imposed by governments of every major economy that lead to shut the manufacturing units worldwide. As hospitals are packed with COVID-19, many non-COVID patients are facing difficulty in finding hospitals to consult for the treatment.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising geriatric population and increasing number of osteoporosis patients globally are propelling the market growth.
  • Increasing clinical trials and improved diagnostic facilities provided by private & public medical institutions are driving the market growth.
  • Ongoing awareness campaigns related to the treatment of osteoporosis disorder is one of the factors fueling the growth of the market.
  • Expiring patents of robust drugs is expected to hamper the market growth in the coming years.
  • Adverse side effects of medications and stringent government regulations along with delaying in drug approvals are some of the key challenging factors hindering the market.
  • Rising technological advancement and introduction of new drugs by pharmaceutical industry with better efficacy to treat osteoporosis are offering great opportunity to trigger the market expansion in the near future.

Scope of the Report

The report on the global anti-osteoporosis therapy & fracture healing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Anti-osteoporosis Therapy & Fracture Healing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Ibandronate, Biophosphonates, Zoledronic Acid, Alendronate, Risedronate, Selective Estrogen Receptor Modulators [Strontium Ranelete and Raloxifene], and Others) and Applications (Injectable, Oral, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Novartis International AG; F. Hoffmann La Roche Ltd.; GlaxoSmithKline Plc.; Eli Lilly and Co.; Merck and Company, Inc.; Pfizer Inc. Amgen Inc.; and Teva Pharmaceutical Industries Ltd.

Market Segment Insights

Bisphosphonates segment is expected to grow at a rapid pace

Based on types, the global anti-osteoporosis therapy & fracture healing market is segmented into ibandronate, biophosphonates, zoledronic acid, alendronate, risedronate, selective estrogen receptor modulators, and others. The selective estrogen receptor modulators segment is bifurcated into strontium ranelete and raloxifene. The bisphosphonates segment is expected to grow at a rapid pace in coming years owing to the rising demand for target-specific therapeutics among the patients and shift of prescription pattern towards bisphosphonates.


Anti-osteoporosis Therapy & Fracture Healing Market types

Injectable segment is projected to expand at a considerable CAGR

On the basis of applications, the market is segregated into injectable, oral, and others. The injectable segment is projected to expand at a considerable CAGR during the forecast period owing to the high successful rate associated with this injectable treatment. It is used for the treatment of osteoporosis patients with high risk of bone fracture. Other factors such as increasing bone mineral density, reducing cell bone turnover, and compatibility with other drugs to get a synergistic effect on overall treatment are expected to propel the growth of the segment.


Anti-osteoporosis Therapy & Fracture Healing Market application

North America is anticipated to constitute a key market share

In terms of regions, the global anti-osteoporosis therapy & fracture healing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the factors such as increasing cases of osteoporosis patients in the region, well- established healthcare facilities, presence of key players, and availability of branded drugs. For example, according to the report published by the National Osteoporosis Foundation (NOF) in 2020, there were more than 10 million people suffering from osteoporosis in the US. Thus, it is expected to fuel the market growth in the region.

However, the market of Asia Pacific is estimated to expand at a considerable CAGR during the forecast period attributed to the geographical expansion of market leaders, growing investment in R&D activities, and efforts to sell branded drugs & generic treatments at an affordable cost.


Anti-osteoporosis Therapy & Fracture Healing Market region

Segments

Segments Covered in the Report
The global anti-osteoporosis therapy & fracture healing market has been segmented on the basis of
Types

  • Ibandronate
  • Biophosphonates
  • Zoledronic Acid
  • Alendronate
  • Risedronate
  • Selective Oestrogen Receptor Modulators
    • Strontium Ranelete
    • Raloxifene
  • Others

Applications

  • Injectable
  • Oral
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Novartis International AG
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc.
  • Eli Lilly and Co.
  • Merck and Company, Inc
  • Pfizer Inc. Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.

 

Competitive Landscape

Some of the key players competing in the market are Novartis International AG; F. Hoffmann La Roche Ltd.; GlaxoSmithKline Plc.; Eli Lilly and Co.; Merck and Company, Inc.; Pfizer Inc. Amgen Inc.; and Teva Pharmaceutical Industries Ltd.

Zydus Pharma Inc.’s Risedronate, a sodium delayed release tablet, was approved by the United States Food and Drug Administration (FDA) in September 2018. It was designed to use for the treatment of postmenopausal women with osteoporosis. Furthermore, denosumab was authorized by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in April 2018 for Amgen, Inc. This medication was designed to use for the treatment of bone loss caused by long-term glucocorticoid therapy.

Anti-osteoporosis Therapy & Fracture Healing Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-osteoporosis Therapy & Fracture Healing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Anti-osteoporosis Therapy & Fracture Healing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Anti-osteoporosis Therapy & Fracture Healing Market - Supply Chain
  4.5. Global Anti-osteoporosis Therapy & Fracture Healing Market Forecast
     4.5.1. Anti-osteoporosis Therapy & Fracture Healing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Anti-osteoporosis Therapy & Fracture Healing Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Anti-osteoporosis Therapy & Fracture Healing Market Absolute $ Opportunity
5. Global Anti-osteoporosis Therapy & Fracture Healing Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Types
     5.3.1. Ibandronate
     5.3.2. Biophosphonates
     5.3.3. Zoledronic Acid
     5.3.4. Alendronate
     5.3.5. Risedronate
     5.3.6. Selective Oestrogen Receptor Modulators
     5.3.7. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Anti-osteoporosis Therapy & Fracture Healing Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Anti-osteoporosis Therapy & Fracture Healing Demand Share Forecast, 2019-2026
7. North America Anti-osteoporosis Therapy & Fracture Healing Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Types
     7.4.1. Ibandronate
     7.4.2. Biophosphonates
     7.4.3. Zoledronic Acid
     7.4.4. Alendronate
     7.4.5. Risedronate
     7.4.6. Selective Oestrogen Receptor Modulators
     7.4.7. Others
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Anti-osteoporosis Therapy & Fracture Healing Demand Share Forecast, 2019-2026
8. Latin America Anti-osteoporosis Therapy & Fracture Healing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Types
     8.4.1. Ibandronate
     8.4.2. Biophosphonates
     8.4.3. Zoledronic Acid
     8.4.4. Alendronate
     8.4.5. Risedronate
     8.4.6. Selective Oestrogen Receptor Modulators
     8.4.7. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Anti-osteoporosis Therapy & Fracture Healing Demand Share Forecast, 2019-2026
9. Europe Anti-osteoporosis Therapy & Fracture Healing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Types
     9.4.1. Ibandronate
     9.4.2. Biophosphonates
     9.4.3. Zoledronic Acid
     9.4.4. Alendronate
     9.4.5. Risedronate
     9.4.6. Selective Oestrogen Receptor Modulators
     9.4.7. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Anti-osteoporosis Therapy & Fracture Healing Demand Share Forecast, 2019-2026
10. Asia Pacific Anti-osteoporosis Therapy & Fracture Healing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Types
     10.4.1. Ibandronate
     10.4.2. Biophosphonates
     10.4.3. Zoledronic Acid
     10.4.4. Alendronate
     10.4.5. Risedronate
     10.4.6. Selective Oestrogen Receptor Modulators
     10.4.7. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Anti-osteoporosis Therapy & Fracture Healing Demand Share Forecast, 2019-2026
11. Middle East & Africa Anti-osteoporosis Therapy & Fracture Healing Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Anti-osteoporosis Therapy & Fracture Healing Market Size and Volume Forecast by Types
     11.4.1. Ibandronate
     11.4.2. Biophosphonates
     11.4.3. Zoledronic Acid
     11.4.4. Alendronate
     11.4.5. Risedronate
     11.4.6. Selective Oestrogen Receptor Modulators
     11.4.7. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Anti-osteoporosis Therapy & Fracture Healing Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Anti-osteoporosis Therapy & Fracture Healing Market: Market Share Analysis
  12.2. Anti-osteoporosis Therapy & Fracture Healing Distributors and Customers
  12.3. Anti-osteoporosis Therapy & Fracture Healing Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Novartis International AG
     12.4.2. F. Hoffmann La Roche Ltd.
     12.4.3. GlaxoSmithKline Plc.
     12.4.4. Eli Lilly and Co.
     12.4.5. Merck and Company, Inc
     12.4.6. Pfizer Inc. Amgen Inc.
     12.4.7. Teva Pharmaceutical Industries Ltd.

Segments Covered in the Report
The global anti-osteoporosis therapy & fracture healing market has been segmented on the basis of
Types

  • Ibandronate
  • Biophosphonates
  • Zoledronic Acid
  • Alendronate
  • Risedronate
  • Selective Oestrogen Receptor Modulators
    • Strontium Ranelete
    • Raloxifene
  • Others

Applications

  • Injectable
  • Oral
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Novartis International AG
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc.
  • Eli Lilly and Co.
  • Merck and Company, Inc
  • Pfizer Inc. Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.

 

Some of the key players competing in the market are Novartis International AG; F. Hoffmann La Roche Ltd.; GlaxoSmithKline Plc.; Eli Lilly and Co.; Merck and Company, Inc.; Pfizer Inc. Amgen Inc.; and Teva Pharmaceutical Industries Ltd.

Zydus Pharma Inc.’s Risedronate, a sodium delayed release tablet, was approved by the United States Food and Drug Administration (FDA) in September 2018. It was designed to use for the treatment of postmenopausal women with osteoporosis. Furthermore, denosumab was authorized by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in April 2018 for Amgen, Inc. This medication was designed to use for the treatment of bone loss caused by long-term glucocorticoid therapy.

Anti-osteoporosis Therapy & Fracture Healing Market keyplayers

Buy Report